Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Full Monty On Pfizer’s Failed 5-HT6 Alzheimer’s Drug Leaves Hope For Class

Executive Summary

Presentation of data at Alzheimer’s Association International Conference highlights failure of Pfizer’s 5HT6 antagonist PF-05212377, while still leaving room to hope for others in class like Lundbeck’s idalopirdine and Axovant’s RVT-101

Advertisement

Related Content

Can Axovant's RVT-1 Redeem 5HT6 Class After Lundbeck's Idalopirdine Failure?
After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD
Immunotherapies Set To Spark Alzheimer's Drug Market
Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test
Lundbeck's Alzheimer's Strategy Targets Symptoms And Disease Modification
Pfizer's Currency, Patent Pressures Boost Allergan Merger's Importance
Alzheimer's Disease: Learning the Lessons Of The Past To Prepare For The Future
Who Will Get First AD Drug To Market In Over A Decade?
Axovant Builds A Case For GSK’s 5-HT6 Castoff In Alzheimer’s
Alzheimer’s Drugs Take Baby Steps Toward Brighter Future

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096981

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel